Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BSTC's Cash to Debt is ranked higher than
95% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. BSTC: No Debt )
BSTC' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: No Debt

Equity to Asset 0.98
BSTC's Equity to Asset is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BSTC: 0.98 )
BSTC' s 10-Year Equity to Asset Range
Min: -5.34   Max: 0.98
Current: 0.98

-5.34
0.98
Interest Coverage No Debt
BSTC's Interest Coverage is ranked higher than
82% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BSTC: No Debt )
BSTC' s 10-Year Interest Coverage Range
Min: 80.45   Max: 9999.99
Current: No Debt

80.45
9999.99
F-Score: 5
Z-Score: 201.97
M-Score: -3.05
WACC vs ROIC
2.76%
54.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 49.72
BSTC's Operating margin (%) is ranked higher than
98% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. BSTC: 49.72 )
BSTC' s 10-Year Operating margin (%) Range
Min: -296.7   Max: 54.91
Current: 49.72

-296.7
54.91
Net-margin (%) 33.00
BSTC's Net-margin (%) is ranked higher than
96% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. BSTC: 33.00 )
BSTC' s 10-Year Net-margin (%) Range
Min: -300.13   Max: 63.95
Current: 33

-300.13
63.95
ROE (%) 18.37
BSTC's ROE (%) is ranked higher than
95% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. BSTC: 18.37 )
BSTC' s 10-Year ROE (%) Range
Min: -343.89   Max: 61.21
Current: 18.37

-343.89
61.21
ROA (%) 17.73
BSTC's ROA (%) is ranked higher than
97% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. BSTC: 17.73 )
BSTC' s 10-Year ROA (%) Range
Min: -156.91   Max: 53.14
Current: 17.73

-156.91
53.14
ROC (Joel Greenblatt) (%) 208.34
BSTC's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. BSTC: 208.34 )
BSTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -406600   Max: 275.15
Current: 208.34

-406600
275.15
Revenue Growth (3Y)(%) 10.60
BSTC's Revenue Growth (3Y)(%) is ranked higher than
81% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. BSTC: 10.60 )
BSTC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -47   Max: 65.8
Current: 10.6

-47
65.8
EBITDA Growth (3Y)(%) 15.00
BSTC's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. BSTC: 15.00 )
BSTC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 15

0
166.8
EPS Growth (3Y)(%) -100.00
BSTC's EPS Growth (3Y)(%) is ranked higher than
75% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. BSTC: -100.00 )
BSTC' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 76.5
Current: -100

-100
76.5
» BSTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BSTC Guru Trades in Q1 2014

Chuck Royce 100,000 sh (unchged)
Jim Simons 14,900 sh (-5.70%)
» More
Q2 2014

BSTC Guru Trades in Q2 2014

Jim Simons 67,009 sh (+349.72%)
Chuck Royce 100,000 sh (unchged)
» More
Q3 2014

BSTC Guru Trades in Q3 2014

Jim Simons 109,000 sh (+62.66%)
Chuck Royce 86,600 sh (-13.40%)
» More
Q4 2014

BSTC Guru Trades in Q4 2014

Jim Simons 145,101 sh (+33.12%)
Chuck Royce 48,600 sh (-43.88%)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.70
BSTC's P/E(ttm) is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 58.70 )
BSTC' s 10-Year P/E(ttm) Range
Min: 14.34   Max: 109.97
Current: 58.7

14.34
109.97
Forward P/E 51.02
BSTC's Forward P/E is ranked higher than
88% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 51.02 )
N/A
PE(NRI) 57.50
BSTC's PE(NRI) is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 57.50 )
BSTC' s 10-Year PE(NRI) Range
Min: 15.05   Max: 108.5
Current: 57.5

15.05
108.5
P/B 8.10
BSTC's P/B is ranked higher than
62% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. BSTC: 8.10 )
BSTC' s 10-Year P/B Range
Min: 4.65   Max: 525
Current: 8.1

4.65
525
P/S 19.50
BSTC's P/S is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. BSTC: 19.50 )
BSTC' s 10-Year P/S Range
Min: 2.57   Max: 75
Current: 19.5

2.57
75
POCF 43.62
BSTC's POCF is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 43.62 )
BSTC' s 10-Year POCF Range
Min: 1.05   Max: 3172
Current: 43.62

1.05
3172
EV-to-EBIT 33.60
BSTC's EV-to-EBIT is ranked higher than
93% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 33.60 )
BSTC' s 10-Year EV-to-EBIT Range
Min: -124.1   Max: 63.9
Current: 33.6

-124.1
63.9
Shiller P/E 105.20
BSTC's Shiller P/E is ranked higher than
93% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 105.20 )
BSTC' s 10-Year Shiller P/E Range
Min: 66.64   Max: 1000
Current: 105.2

66.64
1000
Current Ratio 37.48
BSTC's Current Ratio is ranked higher than
99% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. BSTC: 37.48 )
BSTC' s 10-Year Current Ratio Range
Min: 0.43   Max: 37.48
Current: 37.48

0.43
37.48
Quick Ratio 37.48
BSTC's Quick Ratio is ranked higher than
99% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. BSTC: 37.48 )
BSTC' s 10-Year Quick Ratio Range
Min: 0.42   Max: 37.48
Current: 37.48

0.42
37.48
Days Sales Outstanding 77.45
BSTC's Days Sales Outstanding is ranked higher than
79% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. BSTC: 77.45 )
BSTC' s 10-Year Days Sales Outstanding Range
Min: 5.36   Max: 299.91
Current: 77.45

5.36
299.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.50
BSTC's Price/Net Cash is ranked higher than
75% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. BSTC: 12.50 )
BSTC' s 10-Year Price/Net Cash Range
Min: 3.38   Max: 65.22
Current: 12.5

3.38
65.22
Price/Net Current Asset Value 11.20
BSTC's Price/Net Current Asset Value is ranked higher than
76% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. BSTC: 11.20 )
BSTC' s 10-Year Price/Net Current Asset Value Range
Min: 1.49   Max: 40.21
Current: 11.2

1.49
40.21
Price/Tangible Book 8.50
BSTC's Price/Tangible Book is ranked higher than
66% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. BSTC: 8.50 )
BSTC' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 475
Current: 8.5

0.59
475
Price/DCF (Projected) 11.60
BSTC's Price/DCF (Projected) is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 11.60 )
BSTC' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 67.37
Current: 11.6

0.7
67.37
Price/Median PS Value 1.40
BSTC's Price/Median PS Value is ranked higher than
81% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. BSTC: 1.40 )
BSTC' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 3.98
Current: 1.4

0.08
3.98
Price/Graham Number 4.40
BSTC's Price/Graham Number is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BSTC: 4.40 )
BSTC' s 10-Year Price/Graham Number Range
Min: 1.15   Max: 2.8
Current: 4.4

1.15
2.8
Earnings Yield (Greenblatt) 3.00
BSTC's Earnings Yield (Greenblatt) is ranked higher than
92% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BSTC: 3.00 )
BSTC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 1259.6
Current: 3

1.6
1259.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
BioSpecifics Technologies Corp was incorporated in Delaware in 1990. It is a biopharmaceutical company engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase for indications in development. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease. In December 2013, FDA approved Auxilium's supplemental Biologics License Application ('sBLA') for XIAFLEX for the treatment of Peyronie's disease. The Company and its licensees face competition from larger pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products. As a biopharmaceutical company, the Company is subject to a large body of legal and regulatory requirements.
» More Articles for BSTC

Headlines

Articles On GuruFocus.com
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 09 2010 
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-03-31 Jan 14 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-06-30 Jan 14 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-09-30 Jan 14 2009 
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market Jan 07 2009 

More From Other Websites
BIOSPECIFICS TECHNOLOGIES CORP Financials Mar 20 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Mar 19 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-K, Annual Report Mar 16 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 13 2015
BioSpecifics posts 4Q profit Mar 13 2015
BioSpecifics posts 4Q profit Mar 13 2015
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2014 Financial Results Mar 13 2015
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2014 Financial Results Mar 13 2015
BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014... Mar 06 2015
BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014... Mar 06 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Mar 04 2015
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences Feb 25 2015
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences Feb 25 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Feb 23 2015
BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog Feb 05 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 02 2015
BioSpecifics Technologies Corp. Announces Approval of XIAPEX® in the EU for the Treatment of... Feb 02 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Jan 12 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
BioSpecifics Announces Positive Opinion by CHMP for XIAPEX® for the Treatment of Peyronie's Disease Dec 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK